Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized Neoantigen Vaccine in Adjuvant EOC
NCT06341907Phase 3
Key facts
- Status
- Recruiting
- Start
- Jan 2024
- Primary completion
- Dec 2026
- Countries
- 1
- Sponsor
- The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Conditions
- epithelial ovarian cancer (EOC)
01
Overview
Phase 3 trial of neoantigen polypeptide immunomodulator in epithelial ovarian cancer (EOC), sponsored by The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University. Primary endpoints: Objective Response Rate at 24 months, Progression-Free Survival at 24 months and 2 more. Started Jan 2024; status: recruiting.
02
Design
1 armNeoantigen polypeptide vaccine
Personalized neoantigen vaccine + poly-ICLC + Conventional Protocol
03
Who it enrols
Patients with stage II-IV epithelial ovarian cancer who are MRD-positive after surgery, with no evidence of disease on imaging or routine blood work.
04
Endpoints
Primary
Objective Response Rate
Progression-Free Survival
Overall Survival
Cancer Antigen 125
Secondary
Safety Index
Beyond the preview
Go deeper on NCT06341907.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06341907.